Alongside the first drug developed by AI entering clinical trials, there have been a number of other instances of the technology being used to aid the discovery of new treatments.
Due to the imperative for secure communication between stakeholders organizing clinical trials, a recent report suggests that blockchain technology could be a ‘perfect’ solution.
BioIVT taps into the advantages of hepatic cells for toxicology evaluations and screening studies, securing exclusive distribution agreement with upcyte.
Although control measures are applied, falsified medicines are present in the supply chain in Niger, with solutions requiring cross-country collaboration, says the country’s Ministry of Health.
The levels of patients enrolling for a clinical trial as a first form of treatment for cancer is 0.1%, whilst also being predominantly made up of white males with private insurance.
As African countries look to secure their supply chains, head of the WHO’s team on fighting falsified and substandard medicine speaks about how to ‘demand quality’.
Year-on-year, the number of trials for advanced therapeutics has doubled, meaning that the UK now represents 12% of all global clinical trials in the area.
With efforts to tackle fake drugs in Africa increasing, the WHO's director-general speaks on the need to shorten the supply chain with local manufacturing.
A study on the disclosure of the results of clinical trials found that a majority did not meet the publication deadline, with non-industry most likely to fail to publish.
Heads of state of seven African countries met in Lomé, Togo, to sign the Lomé Initiative, a political declaration to tackle fake medicine distribution on the continent.
Hikma taps Arestat, a formulation technology for protein- and peptide-based drugs, to develop an injectable medicine, ahead of filing for US FDA approval.
The two companies will combine their digital health services to offer clinical trial participants an inhaler equipped with a sensor to analyze patient adherence.
Almirall enters drug discovery agreement with WuXi Biologics, gaining access to the WuXiBody platform to develop antibodies for the treatment of dermatological diseases.
